Indatuximab ravtansine联合来那度胺或泊马度胺及地塞米松治疗复发难治多发性骨髓瘤的1/2a期研究
这项在美国9家医院开展的多中心开放标签1/2a期研究,纳入64例复发难治多发性骨髓瘤患者,评估CD138抗体药物偶联物Indatuximab ravtansine联合来那度胺或泊马度胺及地塞米松的安全性、疗效和药代动力学。
要点
- Indatuximab ravtansine联合来那度胺的最大耐受剂量为100 mg/m2,并作为联合泊马度胺的2期推荐剂量。
- 常见3-4级不良事件为中性粒细胞减少22%、贫血16%、血小板减少11%。
核心结论
- Indatuximab ravtansine联合免疫调节药物在复发难治多发性骨髓瘤中显示出初步抗肿瘤活性且可耐受,值得进一步评估。
研究设计与样本
- 开放标签、多中心1/2a期研究,在美国9家医院开展,2012年7月3日至2015年6月30日筛查74例,入组64例(86%)。
- 1期主要终点为剂量限制性毒性和最大耐受剂量(2期推荐剂量);2期主要终点为客观缓解率和临床获益反应。
主要发现
- 联合来那度胺组最大耐受剂量为100 mg/m2,并定义为联合泊马度胺的2期推荐剂量。
- 联合来那度胺组临床获益反应85%(39/46),联合泊马度胺组88%(15/17)。
- 两组最常见的3-4级不良事件为中性粒细胞减少14例(22%)、贫血10例(16%)、血小板减少7例(11%)。
- 导致停药的治疗中出现的不良事件发生于35例(55%);5例(8%)不良事件结局为死亡,均未报告与Indatuximab ravtansine相关。
关键数值与推荐
- 联合来那度胺方案:Indatuximab ravtansine 80、100、120 mg/m2静脉给药(每28天周期第1、8、15天),来那度胺25 mg口服(每28天周期第1-21天),地塞米松20-40 mg(每28天周期第1、8、15、22天)。
- 联合泊马度胺方案:Indatuximab ravtansine 100 mg/m2,泊马度胺4 mg口服(每28天周期第1-21天),地塞米松同前。
- 入组标准:年龄≥18岁,复发难治多发性骨髓瘤,ECOG体能状态评分≤2;联合来那度胺组至少一种既往治疗失败;联合泊马度胺组至少两种既往治疗失败(包括来那度胺和硼替佐米)且末次治疗后60天内进展。
临床怎么用
- 对于复发难治多发性骨髓瘤,Indatuximab ravtansine联合来那度胺或泊马度胺及地塞米松显示出初步疗效,可考虑在临床试验中进一步评估。
- 治疗期间需重点监测中性粒细胞减少、贫血和血小板减少等血液学不良事件。
局限性
- 研究为开放标签、非随机设计,样本量较小(共64例),联合泊马度胺组仅17例。
- 联合泊马度胺组患者既往治疗更重,与联合来那度胺组不可直接比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Indatuximab ravtansine (BT062) is an antibody-drug conjugate that binds to CD138 and synergistically enhances the antitumor activity of lenalidomide in preclinical models of multiple myeloma. This phase 1/2a study was done to determine the safety, activity, and pharmacokinetics of indatuximab ravtansine in combination with immunomodulatory drugs in patients with relapsed or refractory multiple myeloma. METHODS: This open-label, phase 1/2a study took place at nine hospital sites in the USA. Eligible patients were aged 18 years or older, had relapsed or refractory multiple myeloma, and ECOG performance status or Zubrod score of 2 or below. Patients who received indatuximab ravtansine with lenalidomide and dexamethasone (indatuximab ravtansine plus lenalidomide) had failure of at least one previous therapy. Patients treated with indatuximab ravtansine with pomalidomide and dexamethasone (indatuximab ravtansine plus pomalidomide) had failure of at least two previous therapies (including lenalidomide and bortezomib) and had progressive disease on or within 60 days of completion of their last treatment. In phase 1, patients received indatuximab ravtansine intravenously on days 1, 8, and 15 of each 28-day cycle in escalating dose levels of 80 mg/m2, 100 mg/m2, and 120 mg/m2, with lenalidomide (25 mg; days 1 to 21 every 28 days orally) and dexamethasone (20-40 mg; days 1, 8, 15, and 22 every 28 days). In phase 2, the recommended phase 2 dose of indatuximab ravtansine was given to an expanded cohort of patients in combination with lenalidomide and dexamethasone. The protocol was amended to allow additional patients to be treated with indatuximab ravtansine plus pomalidomide (4 mg; days 1 to 21 every 28 days orally) and dexamethasone, in a more heavily pretreated patient population than in the indatuximab ravtansine plus lenalidomide group. The phase 1 primary endpoint was to determine the dose-limiting toxicities and the maximum tolerated dose (recommended phase 2 dose) of indatuximab ravtansine, and the phase 2 primary endpoint was to describe the objective response rate (ORR; partial response or better) and clinical benefit response (ORR plus minor response). All patients were analysed for safety and all patients with post-treatment response assessments were analysed for activity. This study is registered with ClinicalTrials.gov, number NCT01638936, and is complete. FINDINGS: 64 (86%) of 74 screened patients were enrolled between July 3, 2012, and June 30, 2015. 47 (73%) patients received indatuximab ravtansine plus lenalidomide (median follow-up 24·2 months [IQR 19·9-45·4]) and 17 (27%) received indatuximab ravtansine plus pomalidomide (24·1 months [17·7-36·7]). The maximum tolerated dose of indatuximab ravtansine plus lenalidomide was 100 mg/m2, and defined as the recommended phase 2 dose for indatuximab ravtansine plus pomalidomide. An objective response for indatuximab ravtansine plus lenalidomide was observed in 33 (71·7%) of 46 patients and in 12 (70·6%) of 17 patients in the indatuximab ravtansine plus pomalidomide group. The clinical benefit response for indatuximab ravtansine plus lenalidomide was 85% (39 of 46 patients) and for indatuximab ravtansine plus pomalidomide it was 88% (15 of 17 patients). The most common grade 3-4 adverse events in both groups were neutropenia (14 [22%] of 64 patients), anaemia (10 [16%]), and thrombocytopenia (seven [11%]). Treatment-emergent adverse events (TEAEs) that led to discontinuation occurred in 35 (55%) of the 64 patients. Five (8%) patients with a TEAE had a fatal outcome; none was reported as related to indatuximab ravtansine. INTERPRETATION: Indatuximab ravtansine in combination with immunomodulatory drugs shows preliminary antitumor activity, is tolerated, and could be further evaluated in patients with relapsed or refractory multiple myeloma. FUNDING: Biotest AG.
引用
- Kelly KR, Ailawadhi S, Siegel DS, et al. Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study. Lancet Haematol. 2021. PMID: 34529955. doi:10.1016/S2352-3026(21)00208-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。